43 completed, 8 unknown, 7 recruiting, 7 terminated. 27 Phase 2, 16 Phase 3, 13 Phase 4, 12 Not applicable, 9 Phase 1.
Follow Dyskinesia, Drug-Induced: new trials by email Literature Review of Dyskinesia, Drug-Induced trials Research Report on Dyskinesia, Drug-Induced
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia IMM02-KORA - Dyskinesia, Medication-induced, Dyskinesia, Drug-Induced | Phase 1 | Not yet recruiting | Immunis, Inc. | 15 | 2026-11-30 | 2026-10-30 |
| A Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms Computer-Assisted Objective Assessment of Extrapyramidal Symptoms - Extrapyramidal Symptoms, Drug-induced Parkinsonism | Not yet recruiting | Shanghai Mental Health Center | 180 | 2026-07-01 | 2026-07-21 | |
| Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities Deutetrabenazine Oral Capsule - Tardive Dyskinesia, Intellectual Disability | Phase 4 | Recruiting | University Hospitals Cleveland Medical Center | 25 | 2026-06-22 | 2026-07-06 |
| Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia NBI-1065890, Placebo - Tardive Dyskinesia | Phase 2 | Recruiting | Neurocrine Biosciences | 100 | 2026-02-06 | 2026-06-23 |
| Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD repetitive Transcranial Magnetic Stimulation - Tardive Dyskinesia, Repetitive Transcranial Magnetic Stimulation | Not applicable | Recruiting | Peking University Sixth Hospital | 62 | 2025-09-08 | 2025-12-05 |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Valbenazine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | Neurocrine Biosciences | 100 | 2025-08-29 | 2026-09-18 |
| Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients Tardive Dyskinesia | Not yet recruiting | Power Life Sciences Inc. | 500 | 2025-02-01 | 2024-01-23 | |
| Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia LPM3770164 sustained release tablet 5 mg, LPM3770164 sustained release tablet 10 mg, LPM3770164 sustained release tablet 20 mg - Tardive Dyskinesia (TD) | Phase 1 / Phase 2 | Recruiting | Luye Pharma Group Ltd. | 120 | 2025-01-14 | 2025-01-22 |
| Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities Valbenazine Oral Capsule - Tardive Dyskinesia, Intellectual Disability | Phase 4 | Withdrawn | Stephen Ruedrich | 2025-01-01 | 2024-10-24 | |
| Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine Valbenazine - Tardive Dyskinesia | Phase 1 | Withdrawn | Yale University | 2024-10-18 | 2025-07-11 | |
| rTMS as an Intervention for Levodopa-induced Dyskinesia active TMS, sham TMS - Dyskinesia, Drug-Induced, Parkinson Disease | Not applicable | Recruiting | Danish Research Centre for Magnetic Resonance | 68 | 2024-08-22 | 2026-08-27 |
| Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets LPM3770164 sustained release tablet - Huntington Disease, Tardive Dyskinesia | Phase 1 | Completed | Luye Pharma Group Ltd. | 16 | 2024-07-31 | 2024-12-12 |
| Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant - Tardive Dyskinesia, Huntington Disease | Phase 1 | Completed | Luye Pharma Group Ltd. | 40 | 2023-12-19 | 2024-12-12 |
| Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes TDtect - Tardive Dyskinesia | Not applicable | Unknown | iRxReminder | 300 | 2023-05-30 | 2024-03-12 |
| Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia Valbenazine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Completed | Neurocrine Biosciences | 59 | 2023-05-09 | 2026-01-16 |
| AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia AV-101, Placebo - Parkinson Disease, Dyskinesia, Medication-Induced | Phase 2 | Unknown | VistaGen Therapeutics, Inc. | 20 | 2022-08-01 | 2021-05-26 |
| A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant - Huntington Disease, Tardive Dyskinesia | Phase 1 | Completed | Luye Pharma Group Ltd. | 104 | 2022-02-25 | 2024-01-29 |
| Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia NLX-112, Placebo - Medication-Induced Dyskinesia | Phase 2 | Completed | Neurolixis SAS | 27 | 2021-11-09 | 2024-04-23 |
| Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia CPL500036 - low dose, CPL500036 - high dose, Placebo - Parkinson Disease, Dyskinesia, Medication-Induced | Phase 2 | Completed | Celon Pharma SA | 105 | 2021-11-02 | 2025-03-04 |
| Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy Dipraglurant - Parkinson Disease, Dyskinesia, Drug-Induced | Phase 2 / Phase 3 | Terminated | Addex Pharma S.A. | 17 | 2021-10-25 | 2025-08-06 |
Showing 20 of 76. Sign in to see all of them.
Tardive Dyskinesia (61) · Schizophrenia (17) · Dyskinesias (13) · Parkinson Disease (13) · Movement Disorders (11) · Psychotic Disorders (7) · Central Nervous System Diseases (4) · Huntington Disease (4) · Neurologic Manifestations (4) · Signs and Symptoms (4) · Intellectual Disability (3) · Nervous System Diseases (3) · Akathisia, Drug-Induced (2) · Bipolar Disorder (2)
Pathological Conditions, Signs and Symptoms (76) · Nervous System Diseases (73) · Central Nervous System Diseases (72) · Neurologic Manifestations (72) · Signs and Symptoms (72) · Movement Disorders (65) · Dyskinesias (63) · Mental Disorders (24) · Brain Diseases (20) · Basal Ganglia Diseases (19) · Chemically-Induced Disorders (19) · Neurotoxicity Syndromes (19) · Poisoning (19) · Drug-Related Side Effects and Adverse Reactions (18)
valbenazine (13) · deutetrabenazine (4) · Olanzapine (3) · Transcranial Magnetic Stimulation (3) · 6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine (2) · Aripiprazole (2) · Levetiracetam (2) · Pyridoxine (2) · Risperidone (2) · Sugars (2) · 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine (1) · Acamprosate (1) · Amantadine (1) · Amisulpride (1) · Asian ginseng (1)
Neurocrine Biosciences (13) · Luye Pharma Group Ltd. (4) · Auspex Pharmaceuticals, Inc. (3) · Addex Pharma S.A. (2) · Beersheva Mental Health Center (2) · Beijing HuiLongGuan Hospital (2) · Danish Research Centre for Magnetic Resonance (2) · Emory University (2) · Shanghai Mental Health Center (2) · Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan (2) · Yale University (2) · Caroff, Stanley N., M.D. (1) · Celon Pharma SA (1) · Centre Hospitalier Universitaire, Amiens (1) · Charite University, Berlin, Germany (1)
United States (36) · China (10) · Canada (8) · Puerto Rico (6) · Germany (5) · Poland (4) · Taiwan (4) · Czechia (3) · France (3) · Israel (3) · Slovakia (3) · Denmark (2) · Hungary (2) · Australia (1) · Belgium (1)
Chris O'Brien, MD (4) · Stanley N Caroff, MD (2) · Stephen Ruedrich, MD (2) · Adrian Newman-Tancredi, PhD (1) · Andreas R Kupsch, MD (1) · Andres Lozano, MD (1) · Charlotte Keywood, MD (1) · Chia-Hsiang Chan, M.D. (1) · Christopher G Goetz, MD (1) · Christopher O'Brien, MD (1) · Dilip V. Jeste, MD (1) · Dongfeng Zhou, Professor (1)
PMID 31617235, PMID 38557959, PMID 28404690, PMID 40265997, PMID 17388711, PMID 17685739, PMID 18312060, PMID 20441726, PMID 20868638, PMID 28320223, PMID 28668671, PMID 28747452, PMID 29141124, PMID 30249417, PMID 30695293, PMID 31296586, PMID 32419679, PMID 32651242, PMID 35995551, PMID 36114799, PMID 37620825, PMID 37722831, PMID 38421921, PMID 39186921
2014 (2), 2005 (1), 2025 (1), R01HD034027 (1), R01MH059101 (1), R43MH114763 (1)